Yafei Zhang

Yafei Zhang

AbbVie Inc - Chicago / United States
Others
AD Scientific Index ID: 5408818
-
person_outline Yafei Zhang's MOST POPULAR ARTICLES
1-) Efficacy and safety of risankizumab for Crohn\'s disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studiesX Gao, T Fujii, BD Ye, JW Chou, K Sugimoto, Q Cao, K Kligys, ...Journal of Gastroenterology and Hepatology 39 (1), 55-65, 202442024
2-) Estimation of causal effect in integrating randomized clinical trial and observational data–an example application to cardiovascular outcome trialY Zhang, LA Lin, L Starkopf, J Chen, WWB WangContemporary Clinical Trials 107, 106492, 202142021
3-) Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn’s Disease: Post Hoc Analysis of the …JF Colombel, S Schreiber, G D’Haens, J Rizzo, K Kligys, J Griffith, ...Journal of Crohn\\\'s and Colitis 18 (6), 818-827, 202422024
4-) Bayesian hierarchical model for safety signal detection in multiple clinical trialsY Zhang, SS Yuan, BA Eagel, H Li, LA Lin, WWB WangContemporary Clinical Trials 99, 106183, 202032020
5-) Integrative analysis of randomized clinical trial and observational study data to inform post-marketing safety decision-makingLA Lin, Y Zhang, W Straus, W WangTherapeutic Innovation & Regulatory Science 56 (3), 423-432, 202222022